• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Study: Gamida Cell’s NiCord cell graft yields fewer infections, shorter hospital stays

April 21, 2017 By Sarah Faulkner

Gamida CellGamida Cell said today that its NiCord cell graft produces fewer infections, shorter hospital stays and shorter time to engraftment compared to standard umbilical cord blood transplantation.

The company’s work was published in Biology of Blood and Marrow Transplantation. 

“Our results indicate that rapid hematopoietic recovery from Gamida Cell’s NiCord transplantation approach is associated with clinical benefit. Reducing the burden of infections is important, as these are a major cause of early morbidity and death of patients following UCB transplantation,” principal investigator Dr. Mitchell Horwitz said in prepared remarks.

The treatment is a graft derived from umbilical cord blood which has been expanded and enriched with stem and progenitor cells. The Jerusalem-based company’s cell graft was designed as an alternative to bone marrow transplantation for patients with blood cancer who do not have a fully matched donor.

“NiCord continues to demonstrate significant advantages over standard UCB transplantation in clinical efficacy and in pharmaco-economic parameters enhancing our understanding of the market potential of the product,” president & CEO Yael Margolin added. “Our Phase III registration trial of NiCord is ongoing in which we hope to reproduce these important results in a larger patient population.”

The study compared 18 patients transplanted with NiCord and 86 patients treated with standard umbilical cord blood transplantation.

Researchers reported that the median time to neutrophil engraftment in NiCord patients was 12.5 days compared to 27 days in standard umbilical cord blood patients. Frequency of infection was 22% for NiCord patients compared to 54% for UCB patients.

The team also noted that NiCord patients had nearly 22 more days out of the hospital in the 1st 100 days compared to standard UCB patients.

Filed Under: Clinical Trials, Featured, Oncology, Stem Cells Tagged With: Gamida Cell

IN CASE YOU MISSED IT

  • Another BD Alaris infusion pump recall is Class I
  • Amgen completes $1.9B acquisition of Five Prime Therapeutics
  • Oncopeptides seeks EU marketing authorization for multiple myeloma treatment
  • Horizon touts data from trials for thyroid eye disease infusion treatment
  • Genentech touts study results for spinal muscular atrophy drug in babies

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS